Ganli Pharmaceutical: GLR2037 tablet completes the first dose to the first subject of Phase I.

Gan Li Pharmaceutical announced that the company's independently developed Class 1 chemical new drug, GLR2037 tablets, is undergoing Phase I clinical trials in China, and has recently successfully completed the first dose to a subject. The drug is a androgen receptor-protein degradation chimeric targeted agent intended for the treatment of late-stage prostate cancer. As of September 30, 2025, the project has accumulated research and development expenses of 58.05 million yuan. Currently, there are no approved PROTAC products on the market globally.